JP2016515519A5 - - Google Patents

Download PDF

Info

Publication number
JP2016515519A5
JP2016515519A5 JP2016503056A JP2016503056A JP2016515519A5 JP 2016515519 A5 JP2016515519 A5 JP 2016515519A5 JP 2016503056 A JP2016503056 A JP 2016503056A JP 2016503056 A JP2016503056 A JP 2016503056A JP 2016515519 A5 JP2016515519 A5 JP 2016515519A5
Authority
JP
Japan
Prior art keywords
antibody
seq
composition
identified
high affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016503056A
Other languages
English (en)
Japanese (ja)
Other versions
JP6482525B2 (ja
JP2016515519A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/029308 external-priority patent/WO2014144763A2/en
Publication of JP2016515519A publication Critical patent/JP2016515519A/ja
Publication of JP2016515519A5 publication Critical patent/JP2016515519A5/ja
Application granted granted Critical
Publication of JP6482525B2 publication Critical patent/JP6482525B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016503056A 2013-03-15 2014-03-14 高親和性抗gd2抗体 Active JP6482525B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361801287P 2013-03-15 2013-03-15
US61/801,287 2013-03-15
PCT/US2014/029308 WO2014144763A2 (en) 2013-03-15 2014-03-14 High affinity anti-gd2 antibodies

Publications (3)

Publication Number Publication Date
JP2016515519A JP2016515519A (ja) 2016-05-30
JP2016515519A5 true JP2016515519A5 (https=) 2017-04-13
JP6482525B2 JP6482525B2 (ja) 2019-03-13

Family

ID=51538371

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503056A Active JP6482525B2 (ja) 2013-03-15 2014-03-14 高親和性抗gd2抗体

Country Status (9)

Country Link
US (1) US10167341B2 (https=)
EP (1) EP2968545B1 (https=)
JP (1) JP6482525B2 (https=)
KR (1) KR102207859B1 (https=)
CN (1) CN105705165B (https=)
AU (1) AU2014228772B2 (https=)
CA (1) CA2903576C (https=)
RU (1) RU2680267C2 (https=)
WO (1) WO2014144763A2 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
CA2976074A1 (en) 2015-02-09 2016-08-18 Memorial Sloan Kettering Cancer Center Multi-specific antibodies with affinity for human a33 antigen and dota metal complex and uses thereof
WO2016130918A1 (en) * 2015-02-12 2016-08-18 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating neuroblastoma
KR20170034132A (ko) 2015-09-18 2017-03-28 현대자동차주식회사 람다 센서의 피독 제거 장치 및 방법
EP3269739A1 (en) * 2016-07-15 2018-01-17 OGD2 Pharma Humanized antibody against o-acetylated gd2 ganglioside (oacgd2)
SG11201907299XA (en) 2017-02-08 2019-09-27 Dragonfly Therapeutics Inc Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
BR112019017256A2 (pt) * 2017-02-20 2020-04-14 Dragonfly Therapeutics Inc proteínas de ligação gd2, nkg2d e cd16
IL268755B2 (en) 2017-02-20 2025-12-01 Dragonfly Therapeutics Inc Proteins that bind her2, nkg2d, and cd16
KR20190140943A (ko) * 2017-04-24 2019-12-20 메모리얼 슬로안 케터링 캔서 센터 항-cd33 항체 제제
JP7517983B2 (ja) * 2017-11-20 2024-07-17 ユリウス-マクシミリアン-ウニヴェルシテート・ヴュルツブルク 非常に低レベルのcd19を発現する骨髄腫細胞を除去するcd19cart細胞
DK3749346T3 (da) 2018-02-08 2024-09-09 Dragonfly Therapeutics Inc Antistof variable domænekombinationer rettet mod nkg2d-receptoren
EA202091887A1 (ru) 2018-02-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Комбинированная терапия рака с применением мультиспецифических связывающих белков, которые активируют естественные клетки-киллеры
WO2019164930A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
CN108948211B (zh) * 2018-07-24 2021-08-20 北京美康基免生物科技有限公司 一种基于靶向gd2的嵌合抗原受体及其应用
WO2020033630A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of use
US12378318B2 (en) 2018-08-08 2025-08-05 Dragonfly Therapeutics, Inc. Proteins binding NKG2D, CD16 and a tumor-associated antigen
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
WO2020041565A1 (en) * 2018-08-22 2020-02-27 Memorial Sloan-Kettering Cancer Center Methods for treating neuroblastoma with combination therapy
RU2708136C1 (ru) * 2019-04-15 2019-12-04 Общество с ограниченной ответственностью "Реал Таргет" Новые белковые конструкции для диагностики и терапии gd2-позитивных заболеваний
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
JP2022532766A (ja) 2019-05-17 2022-07-19 キャンサー プリベンション ファーマシューティカルズ,インコーポレイテッド 家族性腺腫性ポリポーシスを処置するための方法
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2
US20220411535A1 (en) * 2019-11-26 2022-12-29 University Of Utah Research Foundation Compositions and methods for upregulating hla class i on tumor cells
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
PE20231854A1 (es) * 2021-03-24 2023-11-21 Biocad Joint Stock Co Anticuerpo monoclonal o fragmento de union al antigeno del mismo que se une especificamente al gd2 (gangliosido gd2), y uso del mismo
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
CN114456270B (zh) * 2022-03-02 2023-12-22 北京美康基免生物科技有限公司 一种gd2嵌合抗原受体及其应用
US20260021206A1 (en) * 2022-07-25 2026-01-22 Vironexis Biotherapeutics Inc. Adeno-associated virus vectors and methods of their use for reducing the risk of, treating, and preventing metastasis

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4309989A (en) 1976-02-09 1982-01-12 The Curators Of The University Of Missouri Topical application of medication by ultrasound with coupling agent
FR2374910A1 (fr) 1976-10-23 1978-07-21 Choay Sa Preparation a base d'heparine, comprenant des liposomes, procede pour l'obtenir et medicaments contenant de telles preparations
FR2413974A1 (fr) 1978-01-06 1979-08-03 David Bernard Sechoir pour feuilles imprimees par serigraphie
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE448277B (sv) 1985-04-12 1987-02-09 Draco Ab Indikeringsanordning vid en doseringsanordning for lekemedel
US4824659A (en) 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
SE453566B (sv) 1986-03-07 1988-02-15 Draco Ab Anordning vid pulverinhalatorer
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4767402A (en) 1986-07-08 1988-08-30 Massachusetts Institute Of Technology Ultrasound enhancement of transdermal drug delivery
EP0545913B1 (en) 1986-08-18 1999-02-24 Emisphere Technologies, Inc. Delivery systems for pharmacological agents
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
EP0279582A3 (en) 1987-02-17 1989-10-18 Pharming B.V. Dna sequences to target proteins to the mammary gland for efficient secretion
US4873316A (en) 1987-06-23 1989-10-10 Biogen, Inc. Isolation of exogenous recombinant proteins from the milk of transgenic mammals
US6010902A (en) 1988-04-04 2000-01-04 Bristol-Meyers Squibb Company Antibody heteroconjugates and bispecific antibodies for use in regulation of lymphocyte activity
US5601819A (en) 1988-08-11 1997-02-11 The General Hospital Corporation Bispecific antibodies for selective immune regulation and for selective immune cell binding
EP0359096B1 (en) 1988-09-15 1997-11-05 The Trustees Of Columbia University In The City Of New York Antibodies having modified carbohydrate content and methods of preparation and use
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3909708A1 (de) 1989-03-23 1990-09-27 Boehringer Mannheim Gmbh Verfahren zur herstellung bispezifischer antikoerper
ES2096590T3 (es) 1989-06-29 1997-03-16 Medarex Inc Reactivos biespecificos para la terapia del sida.
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5580575A (en) 1989-12-22 1996-12-03 Imarx Pharmaceutical Corp. Therapeutic drug delivery systems
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
TW212184B (https=) 1990-04-02 1993-09-01 Takeda Pharm Industry Co Ltd
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
DE69132709T2 (de) 1990-06-29 2002-06-20 Large Scale Biology Corp., Vacaville Melaninproduktion durch transformierte mikroorganismen
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
ATE300615T1 (de) 1990-08-29 2005-08-15 Genpharm Int Transgene mäuse fähig zur produktion heterologer antikörper
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
EP0557300B1 (en) 1990-10-29 1997-11-19 Chiron Corporation Bispecific antibodies, method of production, and uses thereof
US5582996A (en) 1990-12-04 1996-12-10 The Wistar Institute Of Anatomy & Biology Bifunctional antibodies and method of preparing same
US5404871A (en) 1991-03-05 1995-04-11 Aradigm Delivery of aerosol medications for inspiration
DK0575545T3 (da) 1991-03-15 2003-09-15 Amgen Inc Pegylering af polypeptider
WO1992018629A1 (en) * 1991-04-19 1992-10-29 Genetics Institute, Inc. Recombinant 3f8-type antibodies
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5637481A (en) 1993-02-01 1997-06-10 Bristol-Myers Squibb Company Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
WO1993000951A1 (en) 1991-07-02 1993-01-21 Inhale, Inc. Method and device for delivering aerosolized medicaments
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
DE4207475A1 (de) 1992-03-10 1993-09-16 Goldwell Ag Mittel zum blondieren von menschlichen haaren und verfahren zu dessen herstellung
ZA932522B (en) 1992-04-10 1993-12-20 Res Dev Foundation Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens
ATE182651T1 (de) 1992-06-09 1999-08-15 Hoppe Ag Riegel und türschloss
AU4829593A (en) 1992-09-23 1994-04-12 Fisons Plc Inhalation device
AU5322494A (en) 1992-10-02 1994-04-26 Trustees Of Dartmouth College Bispecific reagents for redirected targeting of low density lipoprotein
CA2147260C (en) 1992-10-19 1999-04-13 Mark Bernard Mecikalski Dry powder inhaler
US5643252A (en) 1992-10-28 1997-07-01 Venisect, Inc. Laser perforator
MD1367C2 (ro) 1992-11-13 2000-11-30 Idec Pharmaceuticals Corporation Metode de tratament al limfomului celulelor B, anticorpi anti-CD20, hibridom.
US5849695A (en) 1993-01-13 1998-12-15 The Regents Of The University Of California Parathyroid hormone analogues useful for treatment of osteoporosis and disorders of calcium meatabolism in mammals
ATE172933T1 (de) 1993-01-19 1998-11-15 Glaxo Group Ltd Aerosol-spender und verfahren zu seiner herstellung
CZ206195A3 (en) 1993-02-12 1996-04-17 Univ Leland Stanford Junior Controlled transcription of target genes and other biological materials
US5514670A (en) 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
DE4337197C1 (de) 1993-10-30 1994-08-25 Biotest Pharma Gmbh Verfahren zur selektiven Herstellung von Hybridomazellinien, die monoklonale Antikörper mit hoher Zytotoxizität gegen humanes CD16-Antigen produzieren, sowie Herstellung bispezifischer monoklonaler Antikörper unter Verwendung derartiger monoklonaler Antikörper und des CD30-HRS-3-Antikörpers zur Therapie menschlicher Tumore
US5814599A (en) 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
JPH09510201A (ja) 1994-03-07 1997-10-14 メダレツクス・インコーポレーテツド 臨床的効用を有する二重特異性分子
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6037453A (en) 1995-03-15 2000-03-14 Genentech, Inc. Immunoglobulin variants
US5886793A (en) 1995-04-04 1999-03-23 Oki Data Corporation Facsimile machine adapted to reduce risk of data loss
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
GB9526100D0 (en) 1995-12-20 1996-02-21 Intersurgical Ltd Nebulizer
JP2000503565A (ja) 1996-01-03 2000-03-28 グラクソ、グループ、リミテッド 吸入装置
WO1997034634A1 (en) * 1996-03-20 1997-09-25 Sloan-Kettering Institute For Cancer Research Single chain fv constructs of anti-ganglioside gd2 antibodies
ES2169299T3 (es) 1996-09-03 2002-07-01 Gsf Forschungszentrum Umwelt Procedimiento para la destruccion de celulas tumorales contaminantes en transplantes de celulas madre utilizando anticuerpos especificos.
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US5955186A (en) 1996-10-15 1999-09-21 Kennametal Inc. Coated cutting insert with A C porosity substrate having non-stratified surface binder enrichment
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
US5879681A (en) 1997-02-07 1999-03-09 Emisphere Technolgies Inc. Compounds and compositions for delivering active agents
US6090381A (en) 1997-02-11 2000-07-18 Immunomedics, Inc. Stimulation of an immune response with antibodies labeled with the . .alpha-galactosyl epitope
US5921447A (en) 1997-02-13 1999-07-13 Glaxo Wellcome Inc. Flow-through metered aerosol dispensing apparatus and method of use thereof
US6884879B1 (en) 1997-04-07 2005-04-26 Genentech, Inc. Anti-VEGF antibodies
BRPI9809391B8 (pt) 1997-04-14 2021-05-25 Amgen Res Munich Gmbh processo para a produção de um receptor de antígeno anti-humano, anticorpo humano e composição farmacêutica
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
IL120943A (en) 1997-05-29 2004-03-28 Univ Ben Gurion A system for administering drugs through the skin
AU750767B2 (en) 1998-01-23 2002-07-25 Immunex Corporation ACPL DNA and polypeptides
ES2434961T5 (es) 1998-04-20 2018-01-18 Roche Glycart Ag Ingeniería de glicosilación de anticuerpos para mejorar la citotoxicidad celular dependiente del anticuerpo
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル, インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
US7273925B1 (en) 1998-12-15 2007-09-25 Brigham And Women's Hospital, Inc. Methods and products for regulating lectin complement pathway associated complement activation
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
CA2388245C (en) 1999-10-19 2012-01-10 Kyowa Kirin Co., Ltd. The use of serum-free adapted rat cells for producing heterologous polypeptides
CA2424977C (en) 2000-10-06 2008-03-18 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2639222T5 (es) 2000-10-06 2023-11-24 Kyowa Kirin Co Ltd Células que producen unas composiciones de anticuerpo
US7666424B2 (en) 2001-10-17 2010-02-23 Sloan-Kettering Institute For Cancer Research Methods of preparing and using single chain anti-tumor antibodies
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
AU2002359568B2 (en) 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP2006516241A (ja) 2002-09-20 2006-06-29 マクギル ユニヴァーシティー Gd2リガンド
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
EP1625165A2 (en) 2003-04-03 2006-02-15 Protein Design Labs, Inc. Inhibitors of integrin alpha5beta1 and their use for the control of tissue granulation
US20040220084A1 (en) 2003-05-02 2004-11-04 Jasbir Sandhu Methods for nucleic acid delivery
PE20050925A1 (es) 2003-11-10 2005-11-29 Schering Corp Anticuerpo recombinante humanizado anti-interleuquina 10
PL1706428T3 (pl) * 2004-01-22 2010-02-26 Merck Patent Gmbh Przeciwciała przeciwnowotworowe o zredukowanym wiązaniu dopełniacza
CN103172731A (zh) 2004-07-15 2013-06-26 赞科股份有限公司 优化的Fc变体
US20090304721A1 (en) 2005-09-07 2009-12-10 Medlmmune, Inc Toxin conjugated eph receptor antibodies
FR2906808B1 (fr) * 2006-10-10 2012-10-05 Univ Nantes Utilisation d'anticorps monoclonaux specifiques de la forme o-acetylee du ganglioside gd2 dans le traitement de certains cancers
MY153074A (en) 2008-08-14 2014-12-31 Teva Pharmaceuticals Australia Pty Ltd Anti-il-12/11-23 antibodies
DK3323830T3 (da) 2010-06-19 2023-09-25 Memorial Sloan Kettering Cancer Center Anti-gd2 antibodies
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
RU2714733C2 (ru) * 2013-03-15 2020-02-19 Мемориал Слоан-Кеттеринг Кэнсер Сентер Технологии мультимеризации
CN105705165B (zh) 2013-03-15 2020-04-24 纪念斯隆-凯特琳癌症中心 高亲和力抗gd2抗体
US11392902B2 (en) 2017-06-06 2022-07-19 United Parcel Service Of America, Inc. Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery

Similar Documents

Publication Publication Date Title
JP2016515519A5 (https=)
US20250057918A1 (en) Interleukin-18 variants and methods of use
JP7420866B2 (ja) 核酸ポリペプチド組成物とその使用
JP7581252B2 (ja) Unaアミダイトおよびその使用
TWI669310B (zh) 能夠結合cd123和cd3的雙特異性單價雙抗體及其用途
RU2015143208A (ru) Высокоаффинные антитела kgd2
TWI596116B (zh) 包含專一性辨識cd38之抗體及硼替佐米(bortezomib)之抗腫瘤組合
JP2019107018A5 (https=)
BR112021011014A2 (pt) Anticorpos anti-claudina e usos destes
JP2020503001A5 (https=)
JP2019504892A5 (https=)
CN108473578A (zh) 治疗癌症的抗pd-1抗体和双特异性抗cd20/抗cd3抗体组合
CN116077647A (zh) 喹啉衍生物与抗体的药物组合
JP2015534577A5 (https=)
JP2013135695A5 (https=)
TW202108181A (zh) 抗trop2抗體及其生產方法、及抗trop2抗體-藥物結合物
KR20220035910A (ko) Car-t 세포의 인시츄 모집, 재프로그래밍 및 방출
CN112654346A (zh) 生物分子包覆颗粒和薄膜及其用途
RU2015119159A (ru) Антитела к интерлейкину 6 и их применение
TW202320827A (zh) 用於治療癌症之檢查點抑制劑和溶瘤病毒的組合
CN119816313A (zh) 含有抗人表皮生长因子受体2(her2)嵌合抗原受体(car)的自然杀伤细胞的给药方法
JPWO2023288241A5 (https=)
JPWO2020237173A5 (https=)
US20240342246A1 (en) Interleukin-12 variants and methods of use
KR20200118010A (ko) 암의 만성 car 치료